Core Viewpoint - TaiLin Bio's stock price has shown volatility, with a year-to-date increase of 56.12%, but a recent decline over the past 20 and 60 days, indicating potential market fluctuations and investor sentiment changes [1]. Financial Performance - For the period from January to September 2025, TaiLin Bio reported revenue of 213 million yuan, a year-on-year decrease of 12.08%, while net profit attributable to shareholders was 14.72 million yuan, reflecting a year-on-year increase of 30.13% [2]. - Cumulative cash dividends since the company's A-share listing amount to 117 million yuan, with 60.1 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 13.61% to 9,437, while the average circulating shares per person increased by 15.76% to 8,058 shares [2]. - Notably, the fund "Noan Multi-Strategy Mixed A" has exited the list of the top ten circulating shareholders [3]. Market Activity - On November 28, TaiLin Bio's stock price fell by 2.02% to 26.65 yuan per share, with a trading volume of 19.08 million yuan and a turnover rate of 0.93%, resulting in a total market capitalization of 3.23 billion yuan [1]. - The net inflow of main funds was 1.1 million yuan, with large orders accounting for 15.25% of purchases and 9.49% of sales [1].

Company Overview - Tailin Biological Technology Co., Ltd. is located in Hangzhou, Zhejiang Province, established on January 8, 2002, and listed on January 14, 2020. The company specializes in the research, manufacturing, and sales of microbial detection and control technology systems, organic analysis instruments, and other pharmaceutical equipment [1]. Business Segmentation - The main business revenue composition is as follows: microbial detection technology series products account for 41.12%, sterile production and contamination control equipment series products account for 40.78%, organic analysis technology series products account for 11.15%, and others account for 6.95% [1]. Stock Performance - On October 27, Tailin Biological's stock fell by 5.14%, trading at 30.44 yuan per share, with a transaction volume of 85.03 million yuan and a turnover rate of 3.58%. The total market capitalization is 3.689 billion yuan [1]. Fund Holdings - According to data from major fund holdings, one fund under Nuoan Fund has a significant position in Tailin Biological. The Nuoan Multi-Strategy Mixed A Fund (320016) increased its holdings by 286,000 shares in the second quarter, bringing the total to 511,200 shares, which represents 0.44% of the fund's net value, making it the fourth-largest holding [2]. Fund Performance - The Nuoan Multi-Strategy Mixed A Fund (320016) was established on August 9, 2011, with a latest scale of 1.399 billion yuan. Year-to-date returns are 68.76%, ranking 345 out of 8,226 in its category; one-year returns are 84.01%, ranking 158 out of 8,099; and since inception, the return is 225.7% [2]. Fund Management - The fund is managed by Kong Xianzheng and Wang Haichang. As of the latest update, Kong has been in position for 4 years and 336 days, with a total fund asset size of 4.607 billion yuan, achieving a best return of 84.01% and a worst return of -16.74% during his tenure. Wang has been in position for 3 years and 98 days, managing assets of 2.529 billion yuan, with a best return of 71.06% and a worst return of -18.8% [3].

Group 1 - The core viewpoint of the news is that Tailin Bio has seen a stock price increase of 5.07%, reaching 33.15 CNY per share, with a total market capitalization of 4.018 billion CNY [1] - Tailin Bio, established on January 8, 2002, and listed on January 14, 2020, specializes in the research, manufacturing, and sales of microbial detection and control technology systems, as well as organic analysis instruments [1] - The main revenue composition of Tailin Bio includes 41.12% from microbial detection technology products, 40.78% from sterile production and contamination control equipment, 11.15% from organic analysis technology products, and 6.95% from other sources [1] Group 2 - The fund "Noan Multi-Strategy Mixed A" (320016) has entered the top ten circulating shareholders of Tailin Bio, holding 511,200 shares, which is 0.67% of the circulating shares [2] - The fund has achieved a year-to-date return of 61.81%, ranking 429 out of 8,174 in its category, and a one-year return of 121.96%, ranking 230 out of 7,981 [2] - The fund manager, Kong Xianzheng, has a tenure of 4 years and 291 days, with a best fund return of 76.44% during his management [3] Group 3 - The fund "Noan Multi-Strategy Mixed A" increased its holdings in Tailin Bio by 286,000 shares in the second quarter, making it the fourth-largest holding in the fund [4] - The current floating profit from the investment in Tailin Bio is approximately 817,900 CNY [4]